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Abstract
Background: Antiretroviral therapy (ART) has markedly decreased the morbidity and mortality due to HIV/AIDS.
ART regimen change is a major challenge for the sustainability of human immunodeficiency virus (HIV) treatment
program. This is found to be a major concern among HIV/AIDS patients in a resource-limited setting, where
treatment options are limited.
Objectives: The aim of this review is to generate the best available evidence regarding the magnitude of first-
line antiretroviral therapy regimen change and the causes for regimen change among HIV patients on ART in
Ethiopia.
Methods: The reviewed studies were accessed through electronic web-based search strategy from PubMed
Medline, EMBASE, Hinari, Springer link and Google Scholar. Data were extracted using Microsoft Excel and
exported to Stata software version 13 for analyses. The overall pooled estimation of outcomes was calculated
using a random-effect model of DerSimonian–Laird method at 95% confidence level. Heterogeneity of studies
was determined using I2 statistics. For the magnitude of regimen change, the presence of publication bias was
evaluated using the Begg’s and Egger’s tests. The protocol of this systematic review and meta-analysis was
registered in the Prospero database with reference number ID: CRD42018099742. The published methodology is
available from: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=99742.
Results: A total of 22 studies published between the years 2012 and 2018 were included. Out of 22 articles, 14
articles reported the magnitude of regimen change and consisted of 13,668 HIV patients. The estimated national
pooled magnitude of regimen change was 37% (95% CI: 34, 44%; Range: 15.1–63.8%) with degree of heterogeneity (I2),
98.7%; p-value < 0.001. Seventeen articles were used to identify the causes for first-line antiretroviral therapy regimen
change. The major causes identified were toxicity, 58% (95% CI: 46, 69%; Range: 14.4–88.5%); TB co-morbidity, 12%
(95% CI: 8, 16%; Range: 0.8–31.7%); treatment failure, 7% (95% CI: 5, 9%; Range: 0.4–24.4%); and pregnancy, 5% (95% CI:
4, 7%; Range: 0.6–11.9%).
Conclusions: The original first-line regimen was changed in one-third of HIV patients on ART in Ethiopia. Toxicity of
the drugs, TB co-morbidity, treatment failure, and pregnancy were the main causes for the change of the first-line
regimen among HIV patients on antiretroviral therapy.
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Background
Worldwide, a total of 36.7 million individuals were
infected with human immunodeficiency virus (HIV) [1].
In June 2017, 53% of all people living with HIV were
receiving antiretroviral therapy (ART) [2]. Sub-Sahara
Africa remains the region most heavily affected by HIV.
In eastern and southern Africa, a total of 19 million indi-
viduals were living with HIV [1] and 11.7 million indi-
viduals received antiretroviral treatment, representing
60% of HIV positive individuals in the region in 2016
[2]. Similarly, HIV infection in Ethiopia continues to
pose a threat to the lives of people. Based on a report
from Ethiopian demographic health survey (EDHS), the
estimated prevalence of HIV was 1.2% among men and
women of the 15–49 age group in Ethiopia [3]. The
number of people enrolled in ART rose from 900 in
2005 to 300,000 in 2010, and 436,000 in 2017 and the
number of facilities providing ART services increased
from four in 2003 to 481 in 2009 and 1361 in 2017 [4–6].
Highly active antiretroviral therapy (HAART) changes
HIV/AIDS from diseases with a high mortality rate to
manageable chronic diseases by decreasing the progres-
sion of AIDS and reducing HIV-related illness and
deaths. Treatment change and poor adherence, however,
restrict the therapeutic success and sustainability of the
original regimen. In addition to the poor adherence to
the antiretroviral drug, severe adverse effects of the drug
and treatment failure complicate the entire management
of antiretroviral therapy [7–9]. HAART regimens com-
monly require changes, which often involve switches of
multiple medications simultaneously. As a result, treatment
change of therapy has become a common phenomenon
and hence limitation of treatment option has turned out
the major concern of the future HAART and HIV/AIDS
patients [10, 11].
Ineffectiveness of antiretroviral therapy and regimen
change can be caused by many factors. A rationale for
therapy change can be acute and chronic toxicities,
concurrent clinical situations, development of treatment
failure, poor adherence, a sub-optimal regimen, co-
morbidity and a pregnancy desire [12, 13]. Change in
the regimen lead in a number of challenges; reducing
both the duration and the possibility of viral control due
to cross-resistance between different alternative drugs
and overlapping toxicity between and within an anti-
retroviral drug class. Subsequently, the likelihood that
successful HAART will last a life time is poor [14–16].
Therefore, optimizing the limited available combined
anti-retroviral regimen is essential in order to improve
the long term access and sustainability of HIV treatment
program.
Unless absolutely needed, ART regimen is not chan-
ged. Once a drug combination is modified, it can no lon-
ger be given to the same patient again because it causes
significant morbidity and poor quality of life [17]. Most
ART programs in low- and middle- income settings
follow the World Health Organization (WHO) ART
guidelines that emphasize a public health approach to
ART delivery [18]. This strategy aims at maximizing
population-level survival through a standardized sequen-
cing of available antiretroviral drugs, delivered to indi-
viduals by means of simplified approaches to clinical
decision making and basic laboratory monitoring [19].
Changing of ART regimen is based on clinical parameters
and the drugs are chosen on the basis of their demon-
strated efficacy in suppressing HIV replication and improv-
ing survival of PLHA, low cost and wide availability [20].
However, concerns have emerged about the durability,
safety, tolerability and rational use of ART regimens. Non-
rational use of ART regimen affects the primary goal of
ART, i.e. suppression of the viral load; restoration and pres-
ervation of immunologic function and improved quality of
life may not be achieved. It is important to study the long
term outcome of the ART regimen used and design strat-
egies that increase the durability of the original regimen.
Even though a public health approach ART of WHO
guideline has been used in developing countries [18],
there is a difference in the implementation of the guide-
line of ART regimen change, adherence of the ART
treatment across different countries. Furthermore, the
national guidelines may differ in their choice of the regi-
mens based on the economic status and capacity [21, 22].
This systematic review included studies conducted in
Ethiopia with the aim of providing local evidence as per the
real setting of the population. This assists the clinicians to
focus on the most effective treatment combinations.
In a resource-limited setting like Ethiopia, where treat-
ment options are limited, it is essential to design strat-
egies to increase the durability of the original regimen.
So as to achieve this goal, it is important to determine
the magnitude and causes of initial HAART regimen
change. However, except primary studies conducted in
different part of Ethiopia, the magnitude of change of
first-line ART regimen and the causes responsible for
the change are not well studied in a systematic review
approach. Therefore, this systematic review is aimed to
determine the rate of the initial ART regimen change
and its causes among HIV patients on ART.
The growing access to ART in Ethiopia brings a com-
plex set of issues; when to initiate therapy, what regimen
to use, what drugs to use within each class, when to
change therapy, and what alternative drugs to use. Data
on change of highly active antiretroviral therapy provide
scientific information for clinicians, policy and decision-
makers on the long term strategic approach to initial
and subsequent decisions regarding ART. It assists the
clinicians to focus on the most effective treatment com-
binations. Furthermore, it helps to design appropriate
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measures to increase the duration of the original regi-
men among patients on antiretroviral therapy which
subsequently preserve the future treatment options.
Methods
Study protocol
The Preferred Reporting Items for Systematic Reviews
and Meta-analysis (PRISMA) guideline was used to report
the finding of this review [23]. This systematic review and
meta-analysis was conducted using the PRISMA checklist.
The protocol of this systematic review and meta-analysis
was registered in the Prospero database with reference
number ID: CRD42018099742. The published methodology
is available from: https://www.crd.york.ac.uk/PROSPERO/
display_record.php?RecordID=99742
Identification of records and search strategy
The search strategy aims at finding studies that are both
published and unpublished studies. We searched the fol-
lowing electronic databases: Medline, EMBASE, Hinari,
Springer link and Google Scholar. A three-step search
strategy was utilized in this review. An initial restricted
search of the digital databases was undertaken, followed
by an assessment of the text phrases contained in the
title and abstract, and the index terms used to define the
article. A second search was then performed across all
included databases using all recognized keywords and
index terms. Thirdly, additional studies have been
searched for the reference list of all identified articles.
Subject headings relevant to each database were used,
for example, MeSH for Medline. In addition, google and
hand searching was employed to retrieve grey literature.
Initial keywords used were: ART, antiretroviral, HAART,
chang*, Shift*, Switch*, modif*, substitut*, Ethiopia. The
retrieval was limited to English Language.
Study selection
Records obtained from various digital databases were
exported to Endnote reference software version 7
(Thomson Reuters, Stamford, CT, USA). We used End-
note reference manager to remove duplicated studies. In
order to identify studies that might fulfill the inclusion
criteria, two reviewers (ZA and BM) independently
screened the titles and abstracts. Studies that are deemed
to meet inclusion by title/abstract screening undergone
full-text appraisal by two authors (ZA and BM) inde-
pendently for methodological validity using standardized
critical appraisal instruments from the Joanna Briggs
Institute Meta-Analysis of Statistics Assessment and Re-
view Instrument (JBI-MAStARI). The remaining authors
played an important role in resolving discrepancies be-
tween two authors in order to reach a consensus. Any
disagreements between the reviewers were solved by dis-
cussion. Full texts of included articles were extracted
systematically by using a standardized data extraction
tool from the Joanna Briggs Institute Meta-Analysis of
Statistics Assessment and Review Instruments.
Inclusion and exclusion criteria
During the screening and assessing of full texts for eligi-
bility, there were predefined inclusion-exclusion criteria
to arrive at the final included papers. Observational
studies such as prospective and retrospective cohort
studies, and analytical cross-sectional studies conducted
in Ethiopia addressing the magnitude and/or cause of
first-line ART regimen change were included. Studies
published in the English language were included. All
review articles and original articles conducted outside of
Ethiopia were excluded during initial screening. Articles
with outcome measures that were unrelated, missing or
insufficient and articles with irretrievable full texts were
excluded.
Data extraction
With the help of standardized data abstraction format
prepared in Microsoft Excel, two authors (ZA and BM)
independently extracted necessary data from the articles.
Information about the primary author, study setting,
study design, age, region, year of study, year of publica-
tion, number of study participants, time of data collec-
tion, number of cases (first-line ART regimen change),
and number of each causes reported for regimen change
were extracted from each study.
Critical appraisal of studies
To maintain methodological validity, before inclusion of
the articles two independent reviewers assessed the arti-
cles using the Joanna Briggs Institute (JBI) critical ap-
praisal checklist for studies reporting prevalence data
[24]. The assessment tool consisted of nine questions
about the quality of the study for which articles receive
values representing the extent to which they met the
following criteria: Yes, No, Unclear and Not applicable.
This critical appraisal was conducted to assess the in-
ternal (systematic error) and external (generalizability)
validity of studies and to reduce the risk of biases. The
mean score of the two authors was taken for final deci-
sion and studies with a score greater than or equal to
five out of nine were included.
Outcome measurements
The primary outcome measure is the magnitude of first-
line ART regimen change in Ethiopia. The number of
each case (i.e. first-line regimen change due to any rea-
son) from each article was weighed based on its sample
size, pooled and measured using percentage. The re-
view’s secondary outcome is the causes of the first-line
ART regimen change. The purpose of this review is to
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assess the national pooled estimates of first-line ART
regimen change and the causes for the first-line ART
regimen change among HIV patients.
Data processing and statistical analysis
A Microsoft Excel prepared format was used to extract
data from the included studies. The extracted data were
exported to Stata software version 13 for analyses. Con-
sidering the variation in true effect sizes across the
population, the random effects model of Der Simonian
and Laird was applied at 95% confidence level for the
analyses. Heterogeneity of studies was determined using
I2 statistics. For the magnitude of regimen change,
Begg’s and Egger’s tests were used to evaluate the pres-
ence of publication bias [25, 26]. Funnel plots of log
odds versus 1/SE (log odds) were constructed for the
outcome. A statistical test with a p-value less than 0.05
was considered significant.
Results
Search results
The systematic review and meta-analysis was performed
according to the PRISMA statement [23]. In our litera-
ture search, a total of 484 records were identified from
several sources, including PubMed/Medline, EMBASE,
Google Scholar, HINARI and Springer link. Using End-
note and manual tracing, 89 duplicate articles were re-
moved. A total of 395 records were screened using their
titles and 277 of them were excluded. The remaining
118 records were screened using their abstracts and 89
of them were excluded. Full texts of 29 articles were
then evaluated for eligibility. From these, the outcome of
interest of 7 articles was found missing and/or insuffi-
cient and they were excluded. Finally, 22 articles that
passed the eligibility criteria and quality assessment were
included in this study (Fig. 1). These articles were di-
vided into two groups: those which reported the magni-
tude of regimen change, and those which reported the
causes for regimen change. Some studies reported both
of them.
Study characteristics
A total of 22 studies were included in this systematic
review and meta-analysis (Table 1). Included studies
were published between the years 2012 and 2018. We
included studies that employed both retrospective and
prospective cross-sectional study design. All of the in-
cluded studies were not carried out in the same age
group. Four studies were done on children [27–30]
and thirteen studies were done on adult participants
[15, 31–42]. Four studies had included all the age
ranges [43–46].
Magnitude of drug regimen changes
Out of the 22 articles included in this review, 14 articles
reported the magnitude of regimen change, varying from
15% [43] to 64% [45]. The sample size ranges from 225
[27] to 4809 [37] patients. A total of 13,668 patients
were included in all the studies. The estimated national
pooled magnitude of regimen change was 37% (95% CI:
34, 44%) with degree of heterogeneity (I2), 98.7%; p-
value < 0.001 (Fig. 2).
Causes of regimen change
Out of the 22 articles included in this review, 17 articles
reported the causes for first-line ART regimen change.
Out of the 17 articles, 12 articles mentioned drug toxicity,
as a cause for a regimen change [15, 29, 31, 33, 34, 36, 39,
41, 43–46], three articles described it as a side effect [27,
28, 32], one article describes the reason as adverse drug
reaction (ADR) [38]. In this systematic review, the causes
described as a side effect, hepatotoxicity and ADR were
categorized under toxicity. One study described the causes
(with their numbers) as hepatotoxicity, peripheral neur-
opathy, central nervous system (CNS) toxicity, anemia,
and rash separately [40]. We grouped all this under
toxicity.
Out of the 17 articles included in the assessment of
the causes of magnitude change, 13 articles described
pregnancy [15, 31–34, 36, 38, 39, 41, 43–46]. Fourteen
articles described treatment failure [15, 28, 31–34, 36,
38, 39, 41, 43–46], two studies mentioned clinical failure
[28], and virological failure [32] as a cause. Out of the 17
articles included in the assessment of the causes of mag-
nitude change, only one article didn’t mention TB co-
morbidity as a cause [40]. The most commonly men-
tioned causes for first-line ART regimen were toxicity,
58% (95% CI: 46, 69%; Range: 14.4–88.5%) (Fig. 3); TB
co-morbidity, 12% (95% CI: 8, 16%; Range: 0.8–31.7%)
(Fig. 4); treatment failure, 7% (95% CI: 5, 9%; Range:
0.4–24.4%) (Fig. 5); and pregnancy, 5% (95% CI: 4, 7%;
Range: 0.6–11.9%) (Fig. 6).
The other reasons responsible for the first-line ART
regimen change were stock out problem, 14% (95% CI:
0, 29%) and guideline change, 33% (95% CI: 7, 60%). Out
of the 17 articles, stock out problem was reported by 4
articles [27, 28, 31, 39] and national guideline change was
reported by four articles and it was due to phasing out of
stavudine from the NRTI backbone [27, 29, 39, 40].
Publication bias
Funnel plots of log odds versus 1/SE (log odds) were
constructed for the outcome (magnitude of regimen
change) and the statistical test confirmed that there is
no evidence of publication bias reporting the magnitude
of regimen change (Egger’s test, p = 0.915; Begg’s test,
p = 0.956) (Fig. 7).
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Discussion
This systematic review and meta-analysis was conducted
to estimate the national pooled magnitude of first-line
regimen change among HIV patients in Ethiopia. A total
of 22 original studies addressing the magnitude of regi-
men change and/or the causes for regimen change
among HIV patients in Ethiopia (in resource-poor set-
tings) within the specified timeframe were included.
This review revealed that 37% of HIV patients were
changed their first-line regimen. The regimen change
mentioned consists of any regimen change, i.e. those
recommended by the physicians as well as those due to
different causes. Regardless of the cause, a high rate of
first-line regimen change was reported in this systematic
review. This may indicate poor adherence by patients
and/or poor compliance to guidelines by prescribers.
Treatment success needs strict lifelong drug adherence
and strong guideline compliance in order to achieve
potentially lifelong suppression of HIV replication.
The result of this meta-analysis was lower to a cohort
study conducted in Europe and North America, which
reported 40.3% of patients modified first-line ART [47].
In Swiss HIV cohort studies, higher rates of change were
reported in first line ART regimen [10]. In a study that
compared the approaches to ART showed that, in South
Africa, 22% patients subsequently changed their first-line
regimens from more than 2000 patients receiving
HAART in two towns in Cape Town, South Africa.
While in Switzerland, 53% of patients subsequently
changed their first-line regimens out of 1000 patients
enrolled in the Swiss [48]. The difference in the rate of
regimen change might be due to the difference in socio-
demographic characteristics, healthcare systems, variation
in defining regimen change and study population. The
other possible reasons might be availability viral load test-
ing for monitoring of treatment response might pick regi-
men change due to virological failure earlier in some
countries. Furthermore, limited options of antiretroviral
Fig. 1 PRISMA flow chart describing the selection process
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regimen may limit the clinician decision on first-line ART
regimen change.
Upon initiation of antiretroviral therapy, patients usually
stay permanently on medications. Antiretroviral therapy’s
main objectives are, to keep peak viral load suppression,
restore and preserve immunologic function, improve qual-
ity of life, and decrease morbidity and mortality associated
with HIV. This is achieved through properly regulated
antiretroviral therapy [49]. However, there are many fac-
tors that lead to change/modification of HAART combin-
ation and switch of HAART treatment. These include
long term toxicity and/or adverse drug reaction, treatment
failure (including virological, immunological and clinical
failure), poor adherence, a desire for pregnancy, and/or
co-morbidity [12, 50–53]. This regimen change affects the
success of the treatments to achieve the goal of the United
Nations Program on HIV and AIDS (UNAIDS) [54].
Based on the available data, this systematic review and
meta-analysis revealed to synthesize the evidence on
potential causes of first-line regimen change in Ethiopia.
It indicated that the toxicity (58%), tuberculosis (TB) co-
morbidity (12%), treatment failure (7%) and pregnancy
(5%) were the top four causes for the change of the first-
line regimen. Other causes indicated were program shift
and stock out of the drug. Even though the causes for
first-line ART regimen change are in line with the rec-
ommendation of ART treatment outcomes, the rate of
ART regimen change was found to be high. This pro-
vides important information for clinicians and policy-
makers in the country in order to evaluate and plan for
the future needs of the ART treatment program.
Toxicity was found to be one of the major causes for
the first-line ART regimen change in this review. This
finding is consistent with several primary studies done
Overall  (I^2 = 98.70%, p = 0.00)
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Tadesse B et al (2017)
Haile D, et al(2016)
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Fig. 2 Pooled estimate of magnitude of regimen change in Ethiopia
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in different countries [12, 51, 55, 56]. In all of these pri-
mary studies, the most predictable cause for ART
switching was the toxicity of the drugs. The proposed
reason for this is primarily an inherent property of the
drugs that trigger changes to the ART regimen. Further-
more, it is due to the fact that the occurrence of side ef-
fect alters the quality of life and even result in the death
of a patient and it is a short-term predictor for regimen
change. The most commonly encountered toxicity re-
lated causes for regimen changes ranges from simple up
to life-threatening adverse effects. These include nausea,
rash, anemia and peripheral neuropathy, hepatotoxicity,
mitochondrial damage, and bone marrow toxicity [57].
Toxicity is a potential threat to the effectiveness of
ART. ART regimen change may be an alternative for the
toxicity management, but it should be done considering
the risk of loss of future therapy choices. In health insti-
tutions, less toxic and better-tolerated treatment choices
for HIV should be accessed and used more frequently.
The majority of patients included in the studies used for
this systematic review were started stavudine based regi-
mens [29, 34, 36, 39, 41, 44, 46]. Stavudine is known by
its high toxicity which is found to be the major reasons
for the removal of stavudine from the current regimen
and currently new patients with HIV/AIDS are not start-
ing with stavudine containing regimens. Furthermore,
the occurrence of high rate toxicities could be attributed
to advanced HIV infection. The majority of the patients
included in the articles of this review had advanced dis-
ease stage at baseline (indicated by WHO clinical stage
III and IV) [39, 41, 44, 46]. Patients with advanced dis-
ease stage were more likely to change the initial HAART
regimen. Drug toxicity adversely affects the quality of life
and potential for optimum adherence. Lack of adherence
ultimately leads to the emergence of resistance to anti-
retroviral drugs and treatment failure.
TB-HIV co-morbidity was the second major reason for
changing the first-line ART regimen in this review. This
Overall  (I^2 = 98.53%, p = 0.00)
Sisay MS et al, (2018)
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Fig. 3 Pooled estimates of magnitude of toxicity as a cause for first line regimen change
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might be attributed to the infectiousness properties of
the TB bacilli that cause an opportunistic infection at
any level CD4 count in HIV infected patients. The oc-
currence of TB-HIV co-morbidity after 6 months of ini-
tiation of ART predicts clinical failure that indicates the
need for treatment change [58].
There was a higher chance of changing a first-line
ART regimen in patients who did receive other medications
other than ART. TB drugs especially rifampicin induces
cytochrome 450 enzymes that facilitate the metabolic activ-
ity of the liver, which makes under the therapeutic level of
ART drugs especially nevirapine [59]. Nevirapine contain-
ing regimens were responsible for TB related switches due
to the drug-drug interaction that exists between nevirapine
and rifampicin. In order to avoid this drug interaction, clini-
cians replace the nevirapine with efavirenz based regimens
that have lesser interaction with rifampicin [19, 59].The
other explanation might be the pill burden which is to be
taken simultaneously to treat both AIDS and opportunistic
infection resulting in poor adherence and its common tox-
icity with ART drugs result in the need for change [60].
Treatment failure is another factor for treatment
modification. Treatment failure is described as disease
progression after initiation of ART and occurs when the
anti-HIV treatments can’t control the infection. Anti-
retroviral treatment failure is associated with virologic
failure, immunologic failure, and/or clinical failure [61].
The monitoring of first-line treatment failure and the
decision to start second-line ART regimen are largely
based on the clinical and immunologic assessment of pa-
tients. In a resource-limited setting like Ethiopia, viral
load monitoring, which is the gold standard technique
for diagnosing ART failure, is not widely available.
Clinico-immunologic criterion leads to the unnecessary
changing of first-line ART regimen to second-line ART
regimen in the absence of virologic failure and a late
change to second-line ART regimen. This late change of
first-line ART regimen is related to accumulation of
Overall  (I^2 = 96.02%, p = 0.00)
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Fig. 4 Pooled estimates of the magnitude of TB co-morbidity as a cause for first line regimen change
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mutation and results in resistance to other drugs that
might could be used as a second-line alternative [62, 63].
Optimal management of HIV-infected patients receiving
ART using the viral load test is important for early detec-
tion of treatment failure. Strong HIV treatment program
in the monitoring of patients on first-line treatment to
identify those who are more likely to develop treatment
failure is highly crucial.
Planning pregnancy or being pregnant was also the rea-
son for changing first-line ART regimen in this review. In
Ethiopian, ART treatment change for efavirenz-based regi-
mens is recommended during pregnancy [64]. This shift
was primarily due to the teratogenic effect of efavirenz,
which should be removed during the first-trimester of the
pregnancy. However, another study showed that efavirenz
has similar safety during pregnancy like the other ART’s
and had no increased risk of overall birth defects [65].
Strength and limitation
This is the first systematic review and meta-analysis con-
ducted in Ethiopia to show the national pooled estimates
of the magnitude of first-line ART regimen change
among HIV infected patients. This review adhered to
established standard methods for conducting systematic
reviews. Furthermore, the absence of publication bias
found in this meta-analysis increases the certainty of this
evidence on decision making and resource utilization for
possible preventive measures.
Interpretations of the current study findings should
consider the following important limitations. The ana-
lysis included papers with various definitions of regimen
change. The reviewed articles have also difference in
study design, the type of statistical methods, and the var-
iables included in the analysis. These variations may
have resulted in selection bias or low statistical power,
thus hindering results. Exploring the sources of hetero-
geneity was limited by an insufficient number of the in-
cluded studies. Only a few studies were carried out with
the same age group, which created some difficulties in
conducting sub group analysis (pooling of age-specific
prevalence). Similarly, we were unable to carry out a sub
group analysis using different characteristics. In addition,
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Sisay MS et al, (2018)
Mulugeta A et al(2012)
Jima Y et al(2013)
Study
Teklay G et al(2013)
Kassie Y et al(2014)
Woldemedhin B et al (2012)
Gebremedhin L et al (2014)
Mekonnen E et al (2018)
Anlay DZ et al (2016)
Bilie B et al(2017)
Tadesse W et al (2014)
Geremew A et al (2014)
Wube M etal (2013)
Kasu B et al (2017)
0.07 (0.05, 0.09)
0.22 (0.18, 0.27)
0.07 (0.03, 0.12)
0.03 (0.02, 0.06)
ES (95% CI)
0.00 (0.00, 0.02)
0.01 (0.00, 0.06)
0.03 (0.01, 0.05)
0.10 (0.06, 0.15)
0.03 (0.02, 0.05)
0.03 (0.01, 0.10)
0.01 (0.00, 0.02)
0.13 (0.07, 0.22)
0.21 (0.14, 0.29)
0.03 (0.01, 0.07)
0.24 (0.19, 0.31)
100.00
6.19
6.47
8.47
Weight
9.03
8.20
%
8.61
6.30
8.83
6.99
9.07
4.20
4.33
7.89
5.42
-.2 0 .2 .4
Fig. 5 Pooled estimates of the magnitude of treatment failure as a cause for first line regimen change
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the analysis was limited to only articles published in the
English language; which may have precluded relevant
articles.
Conclusion
This systematic review showed that the original first-line
regimen was changed in one-third of HIV patients on
ART in Ethiopia, which was found to be high. The pro-
portions of individuals who changed the first-line ART
regimen in our resource-constrained country present a
challenge to the our limited treatment choices. Toxicity
of drugs, TB-HIV co-morbidity, treatment failure, and
pregnancy were the main causes for the change of the
first-line regimen. Designing strategies to increase the
durability of the original regimen are essential in such
resource-limited setting, where treatment options are
limited. Selection of the right antiretroviral regimen and
appropriate care, close follow-up and frequent laboratory
result monitoring after ART initiation is necessary to
maintain patients on their initial regimen.
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